Association between hepatocellular carcinoma and tumor necrosis factor alpha polymorphisms in South Korea

Table 3 Genotype frequencies and hepatocellular carcinoma adjusted odd ratios for the TNF-α -1031 T>C, -863 C>A, -857 C>T, -308 G>A, and -238 G>A polymorphisms in hepatocellular carcinoma cases and controls n (%)

Characteristics	Controls, n = 201	HCC cases				HCC cases with HBV
		Cases, n = 157	AOR (95%CI)1	P-value	FDR-P-value	Cases, n = 125	AOR (95%CI)1	P-value	FDR-P-value
TNF-α -1031 T>C, rs1799964
TT	121 (60.2)	99 (63.1)	1.000 (reference)			73 (58.4)	1.000 (reference)
TC	70 (34.8)	47 (29.9)	0.796 (0.487-1.301)	0.362	0.586	42 (33.6)	0.922 (0.550-1.544)	0.756	0.960
CC	10 (5.0)	11 (7.0)	1.308 (0.498-3.436)	0.586	0.586	10 (8.0)	1.724 (0.628-4.729)	0.290	0.580
Dominant (TT vs TC + CC)			0.860 (0.540-1.369)	0.524	0.586		1.013 (0.622-1.650)	0.960	0.960
Recessive (TT + TC vs CC)			1.393 (0.540-3.595)	0.493	0.586		1.745 (0.649-4.693)	0.270	0.580
HWE-P	0.976	0.112				0.268
TNF-α -863 C>A, rs1800630
CC	129 (64.2)	98 (62.4)	1.000 (reference)			74 (59.2)	1.000 (reference)
CA	62 (30.8)	53 (33.8)	1.154 (0.709-1.878)	0.565	0.672	46 (36.8)	1.284 (0.767-2.150)	0.341	0.750
AA	10 (5.0)	6 (3.8)	0.784 (0.255-2.414)	0.672	0.672	5 (4.0)	0.825 (0.253-2.690)	0.750	0.750
Dominant (CC vs CA + AA)			1.109 (0.695-1.768)	0.666	0.672		1.226 (0.749-2.007)	0.418	0.750
Recessive (CC + CA vs AA)			0.734 (0.243-2.222)	0.584	0.672		0.760 (0.238-2.428)	0.643	0.750
HWE-P	0.477	0.723				0.513
TNF-α -857 C>T, rs1799724
CC	142 (70.6)	116 (73.9)	1.000 (reference)			92 (73.6)	1.000 (reference)
CT	53 (26.4)	35 (22.3)	0.841 (0.493-1.432)	0.523	0.697	29 (23.2)	0.840 (0.477- 1.478)	0.545	0.893
TT	6 (3.0)	6 (3.8)	1.816 (0.428-7.714)	0.419	0.697	4 (3.2)	1.110 (0.226- 5.438)	0.898	0.893
Dominant (CC vs CT + TT)			0.930 (0.558-1.548)	0.780	0.78		0.888 (0.516-1.531)	0.670	0.893
Recessive (CC + CT vs TT)			2.091 (0.494-8.860)	0.317	0.697		1.500 (0.312-7.203)	0.612	0.893
HWE-P	0.698	0.120				0.371
TNF-α -308 G>A, rs1800629
GG	181 (90.0)	133 (84.7)	1.000 (reference)			108 (86.4)	1.000 (reference)
GA	18 (9.0)	23 (14.6)	1.949 (0.940- 4.040)	0.073	0.178	17 (13.6)	1.779 (0.821-3.853)	0.144	0.430
AA	2 (1.0)	1 (0.6)	0.936 (0.075-11.646)	0.959	0.959	0 (0.0)	N/A	0.995	0.995
Dominant (GG vs GA + AA)			1.841 (0.911-3.720)	0.089	0.178		1.610 (0.758-3.419)	0.215	0.430
Recessive (GG + GA vs AA)			0.861 (0.069-10.734)	0.908	0.959		N/A	0.995	0.995
HWE-P	0.057	0.996				0.415
TNF-α -238 G>A, rs 361525
GG	180 (89.6)	130 (82.8)	1.000 (reference)			104 (83.2)	1.000 (reference)
GA	20 (10.0)	26 (17.6)	1.634 (0.821-3.251)	0.162	0.324	20 (16.0)	1.491 (0.713-3.117)	0.288	0.576
AA	1 (0.5)	1 (0.6)	N/A	0.993	0.994	1 (0.8)	N/A	0.993	0.993
Dominant (GG vs GA + AA)			1.732 (0.876-3.424)	0.115	0.324		1.614 (0.780-3.340)	0.197	0.576
Recessive (GG + GA vs AA)			N/A	0.994	0.994		N/A	0.993	0.993
HWE-P	0.587	0.807				0.972

¹Adjusted for age, sex, hypertension, diabetes mellitus, drinking status, and smoking status. HCC: Hepatocellular carcinoma; AOR: Adjusted odd ratios; HBV: Hepatitis B virus.